Tempest Therapeutics Announces Clinical Data From Ongoing REDEEM-1 Phase 1/2a Trial Evaluating TPST-2003, CD19/BCMA Dual-Targeting CAR-T Therapy

• 100% complete response (CR) rate among all six efficacy evaluable patients
• Favorable safety profile with no Grade >3 CRS or ICANS
• Prior investigator-initiated trial (IIT) reached median progression free survival (PFS) of 23.1 months, including in patients with extramedullary disease
• 36 patients with relapsed/refractory multiple myeloma treated to date across two studies
• Tempest plans to submit a U.S. IND and, subject to clearance, initiate a U.S. registrational study in 2026
   

BRISBANE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced cell therapy and small molecule product candidates to treat cancer, today announced clinical data from the ongoing REDEEM-1 Phase 1/2a trial evaluating TPST-2003, a CD19/BCMA dual-targeting CAR-T therapy.

TPST-2003 is an autologous CD19/BCMA dual-targeting CAR-T therapy designed to improve response depth and durability in patients with relapsed/refractory multiple myeloma ("rrMM") through a parallel dual-targeting CAR structure designed to address tumor heterogeneity and antigen escape. TPST-2003 is being developed in China by Tempest's partner, Novatim Immune Therapeutics ("Novatim"). Under its agreement with Novatim, Tempest has the exclusive right to develop TPST-2003 outside of China, India, Turkey, and Russia.